Les techniques interventionnelles dans le traitement de l hypertension artérielle: faut-il y croire encore?
|
|
- Caroline Rich
- 6 years ago
- Views:
Transcription
1 Les techniques interventionnelles dans le traitement de l hypertension artérielle: faut-il y croire encore? Prof M Burnier Service de Néphrologie et Hypertension, CHUV, Lausanne Evian 2015
2 Approches non-médicamenteuses du traitement de l hypertension La dénervation rénale: encore en vie? La barostimulation La création d une fistule AV
3 The Renal Sympathetic Nervous System Johns E et al. Compr Physiol 2011, 1:
4 Catieter-based reoam synqatietjc deoervatjpo gpr resjstaot iyqerteosjpo- a numtjceotre sagety aod qrppg-pg-qrjocjqme cpiprt study Krum H et al. Lancet 2009; 373:
5 Symplicity HTN-2: OBP reduction at 6 months Symplicity HTNI. Lancet. 2010;376(9756):
6 RDN Basemjoe vamues aod 6-npoti ciaohes jo systpmjc qressure jo 109 qatjeots 0 Oggjce 24-i Daytjne Njhittjne Uoadkusted Adkusted Fpr basemjoe BP Aod ceoter P<0.03 gpr amm Meao N druhs- 4.7 tp 4.4 (q=0.001) Persu A. et am., Jpuroam pg Hunao Hyqerteosjpo (2013), 1 7
7 RDN 24-i systpmjc bmppd qressure resqpose at 6 npotis -5.9 mmhg % Basemjoe FU Ppst-RDN Persu A. et am., Jpuroam pg Hunao Hyqerteosjpo (2013), 1 7
8 RDN/SE 24-h systolic blood pressure response at 6 months compared with Syst-Eur mmhg mmhg mmhg % % % Baseline FU -75 Baseline FU -75 Baseline FU Post-RDN Syst-Eur placebo Syst-Eur treatment Persu A. et al., Journal of Human Hypertension (2013), 1 7
9 SYMPLICITY HTN-3: Severe Drug-Resistant HTN Office SBP 160 mm Hg 2:1 randomization, blinded and controlled Sham procedure in control patients that included renal angiogram 535 subjects randomized out of 1441 enrolled (63% screen failure rate) 2-week screening process, including maximum tolerated doses of antihypertensives 2 weeks Home BP & HTN med confirmation 1 mo Sham Procedure 2 weeks 3 mo 6 mo Home BP & HTN med confirmation Screening Visit 1 Office SBP 160 mm Hg Full doses 3 meds No med changes in past 2 weeks No planned med changes for 6 mo Screening Visit 2 Office SBP 160 mm Hg 24-h ABPM SBP 135 mm Hg Documented med adherence Renal angiogram; Eligible subjects randomized Renal Denervation 1 mo 3 mo Home BP & HTN med confirmation 2 weeks Primary endpoint 6 mo mo Patients, BP assessors, and study personnel all blinded to treatment status No changes in medications for 6 M Bhatt et al. NEJM DOI: /NEJMoa
10 Prjnary Eggjcacy Eodqpjot Oggjce Systpmjc Bmppd Pressure at 6 Mpotis, 5 nnhh Suqerjprjty Marhjo N = 353 N = 171 RDN Control P value Baseline SBP mo SBP Change P < P < (-6.89, 2.12), P = (Primary analysis with 5 mm Hg superiority margin) Did not meet primary efficacy endpoint Bhatt et al. NEJM DOI: /NEJMoa
11 Secondary Efficacy Endpoint Ambulatory Systolic Blood Pressure at 6 Months, 2 mm Hg Superiority Margin N = 325 N = 159 Baseline SBP RDN Control P value mo SBP Change P < P < (-4.97, 1.06), P = (ITT analysis with 2 mm Hg superiority margin) Did not meet secondary efficacy endpoint Bhatt et al. NEJM DOI: /NEJMoa
12 Pre-Sqecjgjed Subhrpuq Aoamysjs RDN Sham Difference (95% CI) P value Interaction P value All patients (-8.63, 0.49) All patients* (-6.89, 2.12) Diabetics (-11.51, 2.46) Non-diabetics (-9.55, 2.62) Male (-7.63, 3.03) Female (-14.94, 1.65) African American (-7.27, 11.78) c Non-African American (-11.81, -1.44) BMI < (-11.47, 5.93) BMI (-9.76, 1.03) On AA at BL (-17.63, 1.52) Not on AA at BL (-8.42, 1.93) egfr < (-8.29, 9.37) c c egfr (-10.51, 0.06) Age < (-11.06, -0.40) Age (-8.80, 8.99) Any med change (-13.49, 2.67) No med change (-8.83, 1.96) * ITT population, 5 mm Hg superiority margin test mm Hg RDN Better Control Better Bhatt et al. NEJM DOI: /NEJMoa
13 HTN-3: Different Control Response in African American Population Bhatt et al. NEJM DOI: /NEJMoa
14 Multiple Unblinded Trials Show RDN Lowers Blood Pressure Medtronic EnligHTN/St Jude Vessix/Boston Sci. Maya/Covidien Recor Published Sources: 1. Lancet Lancet TCT Journal of Human Hypertension Circulation Clin Res Cardiol J Am Soc Nephrol Eur Heart J TCT Eurointervention EuroIntervention 2013
15 The French DENERHTN study: an open label multicenter RCT Azizi M. et al. The Lancet 2015
16 Schéma de DENERHTN RDN No RDN
17 BP results of DENERHTN
18 Azizi M. et al
19 Resistant hypertension? Assessment of adherence by toxicological urine analysis. Juoh, Omjver et am Jpuroam pg Hyqerteosjpo. 31(4) ,2013 2
20 Mesures des taux urinaires chez 57 patients avec HTA résistante Ratjp = opnbre de tests urjoajres ofhatjgs/opnbres de tests nfdjcaneoteux tptaux
21 Monitoring of drug levels improve BP control in follow-up visits Brjoler et am, JACC, Marci 2014
22 What is the exact location of renal sympathetic nerves? Sakakura K et al. J Am Coll Cardiol 2014;64:635 43
23 Density of SN according to localisation Number of nerves (n) Sakakura K et al. JACC 2014;64: Mahfoud F. et al. JACC, 64, Issue 7, 2014, Pages
24 Position du cathéter de dénervation et réduction des catécholamines
25 In sheeps, renal sympathetic nerve activity and the response to electrical stimulation is back to normal 11 months after RDN Booth LC et a. Hypertension. 2015;65: DOI: /HYPERTENSIONAHA
26 Nouveau programme de développement de la dénervation rénale: SPYRAL HTN Global Clinical Trial Program Approximately 100 patients with moderate- to high-risk hypertension. These studies will be conducted at approximately 20 centers. The SPYRAL HTN-OFF MED study is designed to isolate the effect of renal denervation on blood pressure reduction. The SPYRAL HTN-ON MED study will evaluate the effect of renal denervation on blood pressure in the presence of antihypertensive medication. the SPYRAL HTN-ON MED study requires patients who, despite use of drugs from three of the most common classes of medications prescribed for hypertension, do not achieve adequate blood pressure control. Additionally, patient medication adherence will be closely monitored and there will be a focus on ambulatory blood pressure monitoring (ABPM) to ensure consistency between both arms of the on- and off-medication studies. Medtronic press release, April 2015
27 B. Williams, ESC meeting London 2015
28 An historical perspective on our understanding of baroreceptor physiology Victor, R. G. (2015) Carotid baroreflex activation therapy for resistant hypertension Nat. Rev. Cardiol. doi: /nrcardio
29 Regulation of blood pressure via the baroreflex Courand PY et al. Archives of Cardiovascular Diseases, Volume 107, Issue 12, 2014,
30 The old and the new
31 Barostim neo Improved Technology Platform Procedural Improvements Sjohme emectrpde (vs. twp numtj-qrpohed emectrpdes) Patjeot qpsjtjpojoh Siprter qrpcedure tjne aod ipsqjtam stay (1 ipur aod 1 day vs. 3 ipurs aod 2 days) Substaotjammy jnqrpved sagety qrpgjme Product Improvements Sjhojgjcaotmy snammer mead desjho Lpoher battery mjge MRI cpnqatjbme 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2nd Generation neo +4x improvement 1st Generation Rheos Months from Implant 31
32 The Barostim neo-system From CVRx site
33 Response repeatability of arterial blood pressure and relative total MSNA over time in a patient Karsten Heusser et al. Hypertension. 2010;55:
34 Effect of chronic electric baroreceptor stimulation on LF and HF power during chronic carotid receptor stimulation Wustmann K et al. Hypertension. 2009;54:
35 Correlation between the systolic BP difference and the LF:HF ratio Wustmann K et al. Hypertension. 2009;54:
36 Changes in systolic and diastolic BP after unilateral or bilateral baroreceptor activation therapy. de Leeuw P W et al. Hypertension. 2015;65:
37 Relationship between changes in resting heart rate and resting systolic BP with baroreceptor activation therapy on the left side (A) or on the right side (B). de Leeuw P W et al. Hypertension. 2015;65:
38 Clinical studies with baroreceptor activation in resistant hypertension Zannad F et al. Hypertension. 2015;65:5-15.
39 Effect of chronic baroreceptor activation in DeBut-HT Jan Menne et al. Nephrol. Dial. Transplant. 2013;28:
40 Long-term BP effects of baroreceptor stimulation: the DEBuT-HT study 0 Systolic (Baseline = 193 ± 36 mmhg) Diastolic (Baseline= 111 ± 20 mmhg) Heart Rate (Baseline= 74 ± 12.8 mmhg) N = year 2 years Anti-hypertensive Medications Changes Baseline year years 4 years 5 years 2 years years years Scheffers et al., J. Am. Coll. Cardiol. 2010;56; Kroon et al, ASH years
41 Sustained reduction in 24-hour ABPM in DEBuT-HT 0 Systolic (Baseline: 176 mmhg) Diastolic (Baseline: 107 mmhg) Heart Rate (Baseline: 80 bpm) * -6^ * -13^ -11* ^ *All p values < ^All p values < year (n=15) 2 years (n=8) Scheffers et al., J Am Coll Cardiol 2010;56:1254 8
42 Schematic representation of the Rheos pivotal trial. John D. Bisognano, et al Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension : Results From the Double- Blind, Randomized, Placebo-Controlled Rheos Pivotal Trial Journal of the American College of Cardiology, Volume 58, Issue 7, 2011,
43 Long term results from the Rheos trials Part a reprinted from Bisognano, J. D. et al. J. Am. Coll. Cardiol. 58, (2011), Part b adapted from Bakris, G. L. et al. J. Am. Soc. Hypertens. 6, (2012), Victor, R. G. (2015) Carotid baroreflex activation therapy for resistant hypertension Nat. Rev. Cardiol. doi: /nrcardio
44 Rheos Pivotal Trial Extended Follow-up SBP No BAT BAT Goal N=322 Baseline N=294 1 Year N=255 2 Year N=238 3 Year N=214 4 Year N=114 5 Year N=34 6 Year de Leeuw et al., ESH p<
45 Rheos Study Barostim Demonstrated Pivotal Left Ventricular Trial LV Remodeling Reverse Remodeling with BAT 60 Patjeots grpn Rieps study eorpmmed jo ecipcardjphraqiy substudy SEVERELY ABNORMAL Study assessed ciaohes jo megt veotrjcumar nass jodex (LVMI) agter 12 npotis pg actjve tieraqy MODERATELY ABNORMAL 100 LVMI reductjpo js a strpoh jodjcatpr pg eggectjve ieart gajmure tieraqy At 12 npotis pg BAT, averahe reductjpo pg LVMI was 15 h/n 2 (q < 0.01) tp oprnam raohe n=60 n=60 Baseline 12 Months NORMAL Bisognano, et al, J Am Coll Cardiol
46 Effects of Barostim on Kidney Function N=23 Wallbach, et al., Am J Nephrol 2014
47 Long Term Safety of Rheos Implant 10% 8% 6% 4% 3.28% Safety Events Years 2-5 System/Procedure 0.037% Stroke 0.014% Myocardial Infarction % Rate per Patient Year 2% 0% 1.18% 1.25% 0.23% 0.55% 0.23% Baseline Year 1 Year 2 Year 3 Year 4 Year 5 > 60% Carotid Stenosis (%) de Leeuw et al., ESH/ISH 2014
48 Effet du coupleur artério-veineux (ROX coupler) sur la pression artérielle dans l hypertension résistante Lobo et al, Lancet 2015; 385:
49 Conclusions Renal denervation works in some patients with resistant hypertension but more evidence needs to be acquired. Baroreceptor stimulation appears to be effective and safe in patients with resistant hypertension Preliminary data suggest that the BP changes induced by baroreceptor stimulation are associated with a regression of target organ damages (LVH, albuminuria). However, a larger clinical experience is needed and a larger endpoint trial with morbidity and mortality data should be performed. The ROX device may be effective but is associated to too many side effects and long term risks have not been assessed.
CIC-P Nancy. Disclosures
Pr Patrick Rossignol Inserm 1433 Clinical Investigation Center Hypertension and Heart Failure Unit Association Lorraine pour le Traitement de l Insuffisance Rénale (ALTIR) CHRU, Lorraine University Nancy,
More informationRISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine
RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston
More informationUpdate on renal denervation: Latest data
LINC 2018 Update on renal denervation: Latest data Felix Mahfoud Saarland University Hospital, Germany Potential Conflicts of Interest I have the following potential conflicts of interest to report: Research
More informationBaroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension
Baroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension Robert S. Kieval, VMD, PhD Founder & Chief Technology Officer, CVRx, Inc. Financial Disclosure I,
More informationThe Future of Renal Denervation
The Future of Renal Denervation Ron Waksman, MD, FACC, FSCAI Professor of Medicine, (Cardiology) Georgetown University Director, Cardiovascular Research Advanced Education MedStar Heart Institute, Washington
More informationBaroreflex Stimulation Devices
Medical Policy Manual Surgery, Policy No. 183 Baroreflex Stimulation Devices Next Review: September 2019 Last Review: September 2018 Effective: November 1, 2018 IMPORTANT REMINDER Medical Policies are
More informationCatheter-Based Renal Denervation (RDN)
Hypertension lecture 3: Catheter-Based Renal Denervation (RDN) Adapted from slides prepared by Dr IOEBRAHIM, UNITAS HOSPITAL and others Hypertension Epidemiology 30% Untreated 35% Treated & Controlled
More informationBaroreflex amplificatie als behandeling voor hypertensie: hype of hoop? Wilko Spiering Afdeling Vasculaire Geneeskunde
Baroreflex amplificatie als behandeling voor hypertensie: hype of hoop? Wilko Spiering Afdeling Vasculaire Geneeskunde Nederlands Vasculair Forum, 1 december 2017 Disclosure potential conflicts of interest
More informationRenal Sympathetic Denervation Beyond Hypertension: Therapy for Arrhythmias and for Autonomic Nervous System Dysfunction?
Renal Sympathetic Denervation Beyond Hypertension: Therapy for Arrhythmias and for Autonomic Nervous System Dysfunction? Vivek Y. Reddy, MD Helmsley Trust Professor of Medicine Director, Cardiac Arrhythmia
More informationBaroreflex Stimulation Devices
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationRenal Denervation For Hypertension: Status Update
Samuel N. Steerman, Presenter MD, FACS, name RPVI EVMS Assistant Professor of Surgery Sentara Vascular Specialists Renal Denervation For Hypertension: Status Update Disclosures Disclosures Speaker s Panel
More informationByeong-Keuk Kim, MD, PhD. Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea
Byeong-Keuk Kim, MD, PhD Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea BP change (mmhg) from Baseline to 6 Months (mmhg) Catheter-based renal
More informationRenal sympathetic denervation as a potential treatment for hypertension
Renal sympathetic denervation as a potential treatment for hypertension (Why we must keep going) Dr Andrew SP Sharp Consultant Cardiologist and Honorary Senior Lecturer Royal Devon and Exeter Hospital
More informationDisclosures for Dr. Bhatt
Renal Denervation Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Executive Director of Interventional Cardiovascular Programs, BWH Heart & Vascular Center Professor of Medicine, Harvard Medical School
More informationMINNEAPOLIS September 12, 2012 Medtronic, Inc. (NYSE: MDT) today announced findings
NEWS RELEASE Contacts: Wendy Dougherty Jeff Warren Public Relations Investor Relations 707-541-3004 763-505-2696 FOR IMMEDIATE RELEASE HEALTH-ECONOMIC ANALYSIS SUGGESTS MEDTRONIC SYMPLICITY RENAL DENERVATION
More informationRenal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School
Renal Denervation by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Disclosure Information ACOI Annual Meeting I have the following financial relationships to disclose:
More informationEvidence of Baroreflex Activation Therapy s Mechanism of Action
Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda
More informationRenal denervation for treatment of resistant hypertension
Renal denervation for treatment of resistant hypertension Dr U. Nqebelele Division of Nephrology Department of Internal Medicine Charlotte Maxeke Johannesburg Academic Hospital Thomas Willis: 1621-1675
More informationPreliminary Results of RETREAT
LINC 2015 Leipzig, Germany, Jan 27-30, 2015 Preliminary Results of RETREAT (Renal Denervation with Ultrasound After Failed Radiofrequency Denervation) Horst Sievert, Jan Philipp Kulow, Stefan Bertog, Predrag
More informationNew heart failure RCT: Update on BeAT-HF in the US
New heart failure RCT: Update on BeAT-HF in the US Michael R. Zile, MD Charles Ezra Daniel Professor of Medicine Medical University of South Carolina Chief, Division of Cardiology RHJ Department of Veterans
More informationReal World Experience with Renal Denervation Therapy
JCR 2013 Real World Experience with Renal Denervation Therapy Seung-Hyuk Choi Division of Cardiology Samsung Medical Center Seoul, Korea Hypertension A Major Public Health Burden Astonishing prevalence
More informationCatheter Based Denervation for Heart Failure
Catheter Based Denervation for Heart Failure David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia david.kandzari@piedmont.org
More informationInterventional Therapies for Resistant Hypertension
HOSPITAL CHRONICLES 2012, VOLUME 7, SUPPLEMENT 1: 128 135 HYPERLIPIDEMIA & HYPERTENSION UPDATE Interventional Therapies for Resistant Hypertension Nikolaos Sakellaris, MD, Maria Misailidou, MD ABSTRACT
More informationRenal denervation: Current evidence and remaining uncertainties
Renal denervation: Current evidence and remaining uncertainties Michel Azizi Georges Pompidou European Hospital Hypertension Unit ESH excellence Center Paris Descartes University Clinical Investigation
More informationWith an unrestricted educational grant from. The Interventional Treatment of Resistant Hypertension
With an unrestricted educational grant from The Interventional Treatment of Resistant Hypertension Felix Mahfoud Interventional Cardiology University Hospital Homburg/Saar Germany Dr. Mahfoud graduated
More informationThe Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension Michael Böhm, MD on behalf of the GSR Investigators March 30,
More informationDevice-based Therapies for Resistant Hypertension: Current Status
Mohsin Wali, C Venkata S Ram Therapeutic 10.5005/jp-journals-10043-0070 Device-based Therapies for Resistant Hypertension: Current Status 1 Mohsin Wali, 2 C Venkata S Ram ABSTRACT Resistant hypertension
More informationMP Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension
Medical Policy Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension BCBSA Ref. Policy: 7.01.136 Last Review: 09/19/2018 Effective Date: 09/19/2018 Section:
More informationRelevance of sympathetic overactivity in hypertension and heart failure Therapeutic Implications
Relevance of sympathetic overactivity in hypertension and heart failure Therapeutic Implications Uta C. Hoppe, MD, FESC Dep. of Internal Medicine II Paracelsus University Salzburg Austria Disclosures Within
More informationCarotid Baroreceptor Stimulation: A Potential Solution for Resistant Hypertension
Published online: March 21, 2014 1664 9737/14/0023 0118$39.50/0 Review Carotid Baroreceptor Stimulation: A Potential Solution for Resistant Jun Zhang a Shuyu Zhou a Gelin Xu a, b a Department of Neurology,
More informationΜη φαρμακευτική θεραπεία στην Χρόνια Καρδιακή Ανεπάρκεια Νεότερες συσκευές. Ξυδώνας Σωτήριος, MD, PhD, FESC
ΠΑΝΕΛΛΗΝΙΑ ΣΕΜΙΝΑΡΙΑ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ 2017 ΟΜΑΔΑ ΕΡΓΑΣΙΑΣ ΚΑΡΔΙΑΚΗΣ ΑΝΕΠΑΡΚΕΙΑΣ Μη φαρμακευτική θεραπεία στην Χρόνια Καρδιακή Ανεπάρκεια Νεότερες συσκευές Ξυδώνας Σωτήριος, MD, PhD, FESC Καρδιολογικό Τμήμα,
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationSPYRAL HTN ON MED. Disclosure
Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial Dr. David E. Kandzari Piedmont Heart Institute,
More informationTreating Hypertension With a Catheter..Wait What? David P. Lee, M.D. 22 June 2013 Stanford University
Treating Hypertension With a Catheter..Wait What? David P. Lee, M.D. 22 June 2013 Stanford University COI Medtronic: Research Grant, Consultant Boston Scientific: Research Grant, MAB Worldwide Prevalence
More informationCatheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension
Catheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension Murray Esler, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski,
More informationChristian Daugaard Peters, MD, PhD Department of Renal Medicine Aarhus University Hospital, Denmark Disclosures: None
The effect of renal denervation on central blood pressure and arterial stiffness in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET
More informationHypertension Guidelines Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center
Hypertension Guidelines 2016 Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Speaker Disclosures I disclose that I am a Consultant for: Ablative
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: baroreflex_stimulation_devices 9/2011 4/2018 4/2019 4/2018 Description of Procedure or Service Baroreflex
More informationROX Coupler for treatment-resistant hypertension
EuroScan Technology ROX Coupler for treatment-resistant hypertension Page 1 of 8 Disclaimer: This report is work in progress and should not be used for external distribution without permission from the
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationWhat We've Learned from Simplicity HTN-1,2, and Registries
ANGIOPLASTY SUMMIT-TCTAP 2012 Seoul, Korea, April 24-27, 2012 What We've Learned from Simplicity HTN-1,2, and Registries Horst Sievert, Ann-Kathrin Ziegler, Benjamin Kaltenbach, Ilona Hofmann, Undine Pittl
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More informationClinical Policy Title: Renal denervation
Clinical Policy Title: Renal denervation Clinical Policy Number: 09.03.04 Effective Date: February 1, 2017 Initial Review Date: November 16, 2016 Most Recent Review Date: January 11, 2018 Next Review Date:
More informationAmbulatory Blood Pressure Measurement. Objectives of the Presentation. Methods of Measuring BP: Pros and Cons
Ambulatory Blood Pressure Measurement William B. White, MD Professor of Medicine and Chief, Hypertension and Clinical Pharmacology Calhoun Cardiology Center University of Connecticut School of Medicine
More informationΣύγτρονη θεραπεία της ανθεκτικής σπέρτασης
Σύγτρονη θεραπεία της ανθεκτικής σπέρτασης Κώζηας Τζιούθης Α Παν/κή Καρ/κή Κλινική Ιπποκράηειο Γ.Ν.Α. Resistant or Refractory to treatment Hypertension Office BP>140/90 or 130/80 mm Hg in patients with
More informationStephen G. Worthley 1, Gerard T. Wilkins 2, Mark W. Webster 3,Joseph K. Montarello 1, Paul T. Antonis 4, Robert J. Whitbourn 5, Roderic J.
Six Month Results of First-in-Human Sympathetic Renal Artery Denervation Using a Next Generation Multi-Electrode Renal Artery Denervation System in Patients with Drug-Resistant Hypertension Stephen G.
More informationImplanting a baroreceptor stimulation device for resistant hypertension
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Implanting a baroreceptor stimulation device for resistant hypertension Hypertension (or high blood pressure)
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationSleep Disordered Breathing and HH with Preserved Ejection Fraction:
Sleep Disordered Breathing and HH with Preserved Ejection Fraction: Pr Thibaud DAMY Heart Failure Unit Department of Cardiology CHU Mondor, Créteil, France Definition of HF-PEF The diagnosis of HF-PEF
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationCreation of an Arteriovenous Fistula to Treat Hypertension
Creation of an Arteriovenous Fistula to Treat Hypertension Horst Sievert, Ilona Hofmann, Laura Vaskelyte, Sameer Gafoor, Stefan Bertog, Predrag Matić, Markus Reinartz, Bojan Jovanovic, Kolja Sievert CardioVascular
More informationOLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich,
The effect of renal denervation in patients with advanced heart failure: OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich, 27.08.2012 Disclosures MT: honoraria Bayer,
More informationTreating Hypertension With a Catheter..Wait What? COI 5/3/2013. Worldwide Prevalence of Hypertension Is Increasing
Treating Hypertension With a Catheter..Wait What? David P. Lee, M.D. 4 May 2013 Stanford University COI Medtronic: Research Grant, Consultant Boston Scientific: Research Grant, MAB Worldwide Prevalence
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationCatheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension
Catheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension Henry Krum, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski, Krzysztof Bartus, Boguslaw Kapelak, Horst
More informationManagement of Resistant Hypertension in Diabetes
Management of Resistant Hypertension in Diabetes Soon Hee Lee, M.D., Ph.D. Divisoin of Endocrinology & Metabolism, Department of Internal Medicine, Busan Paik Hospital, College of Medicine, Inje University,
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationMasahiko Fujihara, MD
Verify the efficacy of renal artery stenting to define the predictive factors by physiological assessment with pressure wire gradient VERDICT study Masahiko Fujihara, MD Kishiwada Tokushukai Hospital Osaka,
More informationBackBeat Cardiac Neuromodulation Therapy (CNT) for Immediate, Substantial and Sustained Lowering of Blood Pressure. Daniel Burkhoff MD PhD
BackBeat Cardiac Neuromodulation Therapy (CNT) for Immediate, Substantial and Sustained Lowering of Blood Pressure Daniel Burkhoff MD PhD Director Heart Failure, Hemodynamics and Mechanical Support Research
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationRadiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension
Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension Policy Number: 7.01.136 Last Review: 5/2018 Origination: 11/2015 Next Review: 11/2018 Policy Blue Cross
More informationTranscatheter Perivascular Alcohol- Mediated Renal Denervation
Transcatheter Perivascular Alcohol- Mediated Renal Denervation Wojtek Wojakowski, MD, PhD Medical University of Silesia American Heart of Poland Katowice, Poland I, Wojciech Wojakowski DO NOT have a financial
More informationDevices and Long-Term Outcomes of Renal Denervation for Hypertension
18th ANGIOPLASTY SUMMIT-TCTAP 2013 Seoul, Korea, April 23-26, 2013 Devices and Long-Term Outcomes of Renal Denervation for Hypertension Horst Sievert, Ilona Hofmann, Laura Vaskelyte, Stefan Bertog, Simon
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationNeuromodulation Device Therapy for Treatment of Hypertensive Heart Disease
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp REVIEW Neuromodulation Device Therapy for Treatment of Hypertensive Heart Disease Thomas M. Todoran, MD;
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationRadiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension
Last Review Status/Date: December 2014 Page: 1 of 18 Nerves as a Treatment for Resistant Hypertension Description Radiofrequency ablation (RFA) of the renal sympathetic nerves is a non-pharmacologic treatment
More informationMesures non médicamenteuses pour prévenir et traiter une hypertension artérielle. JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège
Mesures non médicamenteuses pour prévenir et traiter une hypertension artérielle JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège Disclosure No competing interest to declare about this
More informationImportance of Ambulatory Blood Pressure Monitoring in Adolescents
Importance of Ambulatory Blood Pressure Monitoring in Adolescents Josep Redon, MD, PhD, FAHA Internal Medicine Hospital Clinico Universitario de Valencia University of Valencia CIBERObn Instituto de Salud
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationRenal Denervation: Back to the Future?
Renal Denervation: Back to the Future? RCP BHS Hypertension State of the Art 27 th June 2016 Adrian J.B. Brady MD, FRCP(Glasg), FRCPE, FBHS, FESC, FAHA Associate Professor, University of Glasgow Consultant
More informationTreating Hypertension from
Treating Hypertension from Initiation to Resistance: A Case Study Approach Michelle Krause, MD Division of Nephrology University of Arkansas for Medical Sciences Central Arkansas Veteran s Healthcare System
More informationRenal Sympathetic Denervation in Resistant Arterial Hypertension: Long Term and Updated Results
Physiol. Res. 68: 129-133, 2019 doi: 10.33549/physiolres.934008 SHORT COMMUNICATION Renal Sympathetic Denervation in Resistant Arterial Hypertension: Long Term and Updated Results J. H. PEREGRIN 1, J.
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationRenal Artery Denervation New Concepts in Hypertension Treatment
Renal Artery Denervation New Concepts in Hypertension Treatment Istanbul Course of Interventional Cardiology J. Weil Medizinische Klinik II Kardiologie, Angiologie und internistische Intensivmedizin Universitätsklinikum,
More informationTranscatheter Renal Denervation and Hong Kong Experience
Transcatheter Renal Denervation and Hong Kong Experience Dr. Steven Li Siu-lung FACC, FESC, FRCP, FACP Director, Heart Centre, Union Hospital President, Hong Kong Society of Congenital and Structural Heart
More informationNovel Therapies for Resistant Hypertension
HOSPITAL CHRONICLES 2010, 5(2): 76 80 NOVEL THERAPIES Novel Therapies for Resistant Hypertension Nikolaos Sakellaris, MD, Maria Misailidou, MD, Xenia Stathopoulou, MD First Department of Cardiology, Evagelismos
More informationEjection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction
Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus
More informationArticles. Funding Medtronic. Copyright 2018 Elsevier Ltd. All rights reserved.
Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial David E Kandzari,
More informationThe European Society of Cardiology Council on Hypertension
European Heart Journal (2016) 37, 924 936 doi:10.1093/eurheartj/ehw016 The European Society of Cardiology Council on Hypertension The European Society of Cardiology (ESC) Council on Hypertension was officially
More informationImpact of Renal Denervation on 24-hour Ambulatory Blood Pressure: Results from SYMPLICITY HTN-3
Accepted Manuscript Impact of Renal Denervation on 24-hour Ambulatory Blood Pressure: Results from SYMPLICITY HTN-3 George L. Bakris, MD Raymond R. Townsend, MD Minglei Liu, PhD Sidney A. Cohen, MD, PhD
More informationWhen should you treat blood pressure in the young?
ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department
More informationFirst experience with renal denervation in the real life About 6 cases treated with Vessix balloon, Boston scientific
First experience with renal denervation in the real life About 6 cases treated with Vessix balloon, Boston scientific Dr PEYRE Jean-Pascal Private hospital Marseille Beauregard MEET, Nice 2014 ONE CASE
More informationRenal Denervation: The Case for Cardiology
Renal Denervation: The Case for Cardiology John C. Gurley, MD University of Kentucky Presenter Disclosure Information John C Gurley, MD Renal Denervation: The Case for Cardiology FINANCIAL DISCLOSURE:
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationEnligHTN I, First-in-Human Multicenter Study of a Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension
EnligHTN I, First-in-Human Multicenter Study of a Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension Vasilios Papademetriou, MD 1 Prof. Stephen Worthley, MD 2 Costas
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationRenal Denervation for Resistant Hypertension
Renal Denervation for Resistant Hypertension James W. Choi MD FACC FSCAI Cardiology Consultants of Texas Director Interventional Cardiology Fellowship Baylor University Medical Center Baylor Heart & Vascular
More informationUpdate on HTN and ABPM. Raj Padwal Division of General Internal Medicine University of Alberta
Update on HTN and ABPM Raj Padwal Division of General Internal Medicine University of Alberta Disclosures Funding: CIHR, AIHS, HSF, UHF Research Collaboration: Novo Nordisk, CVRx Consulting: Vivus, Medtronic
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationKDIGO Controversies Conference on Blood Pressure in CKD
KDIGO Controversies Conference on Blood Pressure in CKD September 7-10, 2017 Edinburgh, Scotland Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More information